Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Potential Link Between Industrial Pollutants and Acute Myeloid Leukemia Examined

March 8, 2019
By John Schieszer
News
Article

A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML.

Living in an industrial city with exposure to materials/pollution from industrial plants may be an important risk factor for developing acute myeloid leukemia (AML), according to a study published online in the journal Cancer.

Feras M. Ghazawi, MD, PhD, of the University of Ottawa in Ontario, Canada, and colleagues analyzed the incidence and geographic distribution of AML in Canada from 1992 to 2010 using three independent population‐based cancer registries. A total of 18,085 patients were identified during this timeframe, with an AML incidence of 30.61 cases per million individuals per year. The incidence and mortality rates were then examined at the levels of province/territory, city, and postal code.

Five industrial cities in Ontario had incidence rates that were significantly higher than the national average (Sarnia, Sault Ste. Marie, Thunder Bay, St. Catharines, and Hamilton). In one specific postal code in Sarnia, Ontario, the incidence rate was 106.81 cases per million individuals per year, which is more than three times higher than the national average.

“The pollution from local oil refineries and chemical plants in Sarnia may be implicated as a risk factor for AML in that city. Analysis of mortality rates at the province and city levels corroborated the findings from the incidence data,” concluded the authors.

Felipe Samaniego, MD, an associate professor of Lymphoma/Myeloma at MD Anderson Cancer Center in Houston, said this report independently reaches the conclusion that industry centers are associated with the emergence of a higher number of AML cases. However, in some ways it raises more questions than answers, he said.

“It is an area of immensely important and fruitful research. We now have the capacity to look at sum experiences of all studies that identify hotspots of cancers and analyze what is common to most areas that leads to a high incidence of AML,” Samaniego told Cancer Network. “The report implies that pollution is the culprit for AML; however, pollution may be only an associated factor and the real culprit is another factor associated with industry activity.”

Until now, several risk factors have been implicated in AML leukemogenesis, but the epidemiologic distribution and precise triggers for AML in Canada had not been fully investigated, the researchers noted.

Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Related Content
Advertisement

FDA Issues CRL for Dasatinib in CML/ALL

FDA Issues CRL for Dasatinib in CML/ALL

Ariana Pelosci
October 20th 2025
Article

Based on the Good Manufacturing Practice observations, the FDA has given a complete response letter for dasatinib for patients with CML/ALL.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


EO2463 combines 4 synthetic peptides that correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with CD20, CD22, CD37, and CD268, the B lymphocyte-specific lineage markers.

FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma

Tim Cortese
October 16th 2025
Article

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


Site Logo

Prognosis Strategy Exhibits Similar Transplant Outcomes in Select Patients

Roman Fabbricatore
October 5th 2025
Article

A study by the Blood and Marrow Transplant Clinical Trials Network found that a donor search prognosis strategy may move those with cancer to HCT faster.


Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

FDA Receives BLA for Pivekimab Sunirine in Rare Hematologic Malignancy

Russ Conroy
October 1st 2025
Article

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

Related Content
Advertisement

FDA Issues CRL for Dasatinib in CML/ALL

FDA Issues CRL for Dasatinib in CML/ALL

Ariana Pelosci
October 20th 2025
Article

Based on the Good Manufacturing Practice observations, the FDA has given a complete response letter for dasatinib for patients with CML/ALL.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


EO2463 combines 4 synthetic peptides that correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with CD20, CD22, CD37, and CD268, the B lymphocyte-specific lineage markers.

FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma

Tim Cortese
October 16th 2025
Article

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


Site Logo

Prognosis Strategy Exhibits Similar Transplant Outcomes in Select Patients

Roman Fabbricatore
October 5th 2025
Article

A study by the Blood and Marrow Transplant Clinical Trials Network found that a donor search prognosis strategy may move those with cancer to HCT faster.


Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

FDA Receives BLA for Pivekimab Sunirine in Rare Hematologic Malignancy

Russ Conroy
October 1st 2025
Article

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.